NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance

Sorafenib, an oral multikinase inhibitor, is the only approved agent for the treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as its mechanisms of action remain elusive, a better understanding of its anticancer effects is needed. Based on our previous study...

Descripción completa

Detalles Bibliográficos
Autores principales: Emma, M R, Iovanna, J L, Bachvarov, D, Puleio, R, Loria, G R, Augello, G, Candido, S, Libra, M, Gulino, A, Cancila, V, McCubrey, J A, Montalto, G, Cervello, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143401/
https://www.ncbi.nlm.nih.gov/pubmed/27336713
http://dx.doi.org/10.1038/cddis.2016.175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143401/
https://www.ncbi.nlm.nih.gov/pubmed/27336713
http://dx.doi.org/10.1038/cddis.2016.175

Ejemplares similares